Iclusig

(ponatinib) Otsuka

Composition:

• Available in film-coated tablet with each contains 15 mg or 45 mg of ponatinib (as hydrochloride)
   

Indications:

• Indicated in adults patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation
• Also indicated in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation

Drug information updated in ‘The Pace’, including formulation, indication, administration and/or presentation being registered or available in Hong Kong within one year prior to the published date is regarded as new.

The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.